Skip to main content

Table 2 Echocardiographic parameters

From: Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy

 

Con

TP

DM

DM + TP,L

DM + TP,M

DM + TP,H

LVEDD, mm

6.5 ± 0.5

6.6 ± 0.5

5.7 ± 0.8

5.9 ± 0.4

5.5 ± 0.7

5.3 ± 1.1

LVEDD index, um/g

14.3 ± 1.2

14.4 ± 1.1

23.9 ± 3.4*

22.0 ± 2.9*

22.2 ± 2.1*

21.1 ± 4.6*

LVESD, mm

3.8 ± 0.3

3.8 ± 0.4

3.8 ± 0.6

3.7 ± 0.3

3.2 ± 0.3

3.2 ± 0.9

LVESD index, um/g

8.3 ± 0.7

8.2 ± 0.9

16.0 ± 2.5*

13.7 ± 2.2*

13.0 ± 1.1

12.6 ± 3.4

LVEF,%

78.2 ± 2.6

77.5 ± 3.1

67.8 ± 2.6*

73.7 ± 2.5

74.8 ± 3.8#

74.4 ± 3.8#

FS,%

43.2 ± 2.6

42.7 ± 3.3

35.0 ± 1.6*

39.5 ± 2.4

40.8 ± 3.3

40.0 ± 3.7

  1. LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, FS fractional shortening. TP, L low-dose triptolide (100 μg/kg/day), TP, M medium-dose triptolide (200 μg/kg/day); TP, H high-dose triptolide (400 μg/kg/day). *P < 0.05 versus Con; #P < 0.05 versus DM.